Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro⋯A possible explanation for their mechanism of action in treating multiple myeloma

International Immunopharmacology

Volumn 12, Issue 2, 2012, Pages 441-446

  Shannon, E ^a   Sandoval, F ^a   Greig, N ^b   Stagg, P ^c  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c Medical Oncology   (United States)

Author keywords

Dexamethasone; IgG; IgM; Lenalidomide; Thalidomide

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 2; INTERLEUKIN 6; LENALIDOMIDE; THALIDOMIDE;

ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOPLASM; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG STRUCTURE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; IN VITRO STUDY; MULTIPLE MYELOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CELLS, CULTURED; DEXAMETHASONE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN-2; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MULTIPLE MYELOMA; POKEWEED MITOGENS; THALIDOMIDE;

EID: 84856775789     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.12.023     Document Type: Article

References (30)

1. P. Richardson, T. Hideshima, and K. Anderson Thalidomide: emerging role in cancer medicine Annu Rev Med 53 2002 629 657
2. B. Ladizinski, E. Shannon, M. Sanchez, and W. Levis Thalidomide and analogs: potential for immunodulation and inflammatory and neoplastic dermatologic disorders J Drugs Dermatol 9 7 2010 1 14
3. S. Singhal, J. Mehta, R. Desikan, D. Ayers, P. Roberson, and P. Eddlemon Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 21 1999 1565 1571 (18)
4. S.V. Rajkumar, S.R. Hayman, M.Q. Lacy, A. Dispenzieri, S.M. Geyer, and B. Kabat Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma Blood 15;106 13 2005 4050 4053
5. I.P. Kahawita, and D.N. Lockwood Towards understanding the pathology of erythema nodosum leprosum Trans R Soc Trop Med Hyg 102 4 2008 329 337
6. B. Naafs Current views on reaction in leprosy Indian J Lepr 72 2000 97 122
7. T.A. Waldmann, and S. Broder Polyclonal B-cell activators in the study of the regulation of immunoglobulin synthesis in the human system F.J. Dixon, H.G. Kunkel, Adv Immunol Vol. 32 1982 Academic Press New York 1 63
8. E.J. Shannon, and F. Sandoval Thalidomide inhibited the synthesis of IgM and IgG whereas thalidomide + dexamethasone and dexamethasone alone acted as co-stimulants with pokeweed and enhanced their synthesis Int Immunopharmacol 10 4 2010 487 492
9. Eriksson T, Pharmacokinetics of the enantiomers of thalidomide PhD Thesis. Department of Clinical Pharmacology, Lund University, Lund and Hospital Pharmacy, Malmö University Hospital, Sweden, 1997.
10. E.J. Shannon, R. Noveck, F. Sandoval, B. Kamarth, and M. Kearney Thalidomide suppressed IL-6 but not TNF-α in volunteers with experimental endotoxemia Transl Res 150 5 2007 275 280
11. E.J. Shannon, and F. Sandoval Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative Immunopharmacology 31 1 1995 109 116
12. 3]-thymidine-a dependency on the stimulant Int Immunopharmacol 2002 1143 1153
13. 4 + cells is blood Immunopharmacology 46 2000 175 179
14. A.K. Hsu, H. Quach, T. Tai, H.M. Prince, S.J. Harrison, and J.A. Trapani The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy Blood 3;117 5 2011 1605 1613
15. A.K. Gandhi, J. Kang, L. Capone, A. Parton, L. Wu, and L.H. Zhang Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function Curr Cancer Drug Targets 10 2 2010 155 167
16. H. Ludwig, D.M. Nachbaur, E. Fritz, M. Krainer, and H. Huber Interleukin-6 is a prognostic factor in multiple myeloma Blood 15;77 12 1991 2794 2795
17. J.B. Splawski, L.M. McAnally, and P.E. Lipsky IL-2 dependence of the promotion of human B cell differentiation by IL-6 (BSF-2) J Immunol 15;144 2 1990 562 569
18. A. Muraguchi, T. Hirano, B. Tang, T. Matsuda, Y. Horii, and K. Nakajima The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells J Exp Med 1;167 2 1988 332 344
19. A.S. Fauci, K.R. Pratt, and G. Whalen Activation of human B lymphocytes. IV. Regulatory effects of corticosteroids on the triggering signal in the plaque-forming cell response of human peripheral blood B lymphocytes to polyclonal activation J Immunol 119 2 1977 598 603
20. D.A. Cooper, M. Duckett, P. Hansen, V. Petts, and R. Penny Glucocorticosteroid enhancement of immunoglobulin synthesis by pokeweed mitogen-stimulated human lymphocytes. III. Common variable immunodeficiency Clin Exp Immunol 45 2 1981 399 408
21. W.T. Butler, and R.D. Rossen Effects of corticosteroids on immunity in man. I. Decreased serum IgG concentration caused by 3 or 5 days of high doses of methylprednisolone J Clin Invest 52 10 1973 2629 2640
22. R. McMillan, R.L. Longmire, R. Yelenosky, J.E. Lang, V. Heath, and C.G. Craddock Immunoglobulin synthesis by human lymphoid tissues: normal bone marrow as a major site of IgG production J Immunol 109 6 1972 1386 1394
23. J. Sheskin Thalidomide in the treatment of lepra reactions Clin Pharmacol Ther 6 1965 303
24. The Merck index 11th ed. 1989 Thalidomide page 1458
25. E.J. Shannon, R.O. Miranda, M.J. Morales, and R.C. Hastings Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy Scand J Immunol 13 6 1981 553 562
26. J.P. Gusdon, and C. Cohen Effect of thalidomide on the antibody response Am J Obstet Gynecol 1964 952 956
27. M. Vilanova, A. Ribeiro, J. Carneiro, and M. Arala-Chaves The effects of thalidomide treatment on autoimmune-prone NZB and MRL mice are consistent with stimulation of the central immune system Scand J Immunol 40 1994 546 548
28. T. Paravar, and D.J. Lee Thalidomide: mechanisms of action Int Rev Immunol 27 3 2008 111
29. The Merck index 14th ed. 2006 Thalidomide page 1592
30. P. Haslett, P. Roche, C. Butlin, M. Macdonald, N. Shrestha, and R. Manandhar Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation J Infect Dis 192 2005 2045 2053